Dexmedetomidine

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Conscious Sedation

Conditions

Conscious Sedation

Trial Timeline

Oct 1, 2005 → Jul 1, 2006

NCT ID

NCT00226785

About Dexmedetomidine

Dexmedetomidine is a phase 3 stage product being developed by Orion Corporation for Conscious Sedation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00226785. Target conditions include Conscious Sedation.

What happened to similar drugs?

1 of 2 similar drugs in Conscious Sedation were approved

Approved (1) Terminated (0) Active (1)

✅Dexmedetomidine + PropofolPfizerApproved

🔄AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03813277	Approved	Completed	Mar 21, 2017	May 21, 2018	ICU Sedation
NCT02252523	Phase 2	UNKNOWN	Apr 1, 2014	Apr 1, 2015	Acute Brain Injuries
NCT01266252	Phase 3	Completed	Jul 28, 2011	Apr 10, 2018	Mechanically-ventilated Neonates With Single-organ Respiratory Failure
NCT00747721	Phase 1	Completed	Sep 1, 2008	Feb 1, 2009	Pharmacokinetics
NCT00226785	Phase 3	Terminated	Oct 1, 2005	Jul 1, 2006	Conscious Sedation

Competing Products

2 competing products in Conscious Sedation

See all competitors

Product	Company	Stage	Hype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI	Eisai	Phase 3	40
Dexmedetomidine + Propofol	Pfizer	Approved	43